For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Verona Pharma Plc ADR’s stock clocked out at $59.94, up 1.63% from its previous closing price of $58.98. In other words, the price has increased by $1.63 from its previous closing price. On the day, 1.23 million shares were traded. VRNA stock price reached its highest trading level at $60.45 during the session, while it also had its lowest trading level at $59.37.
Ratios:
To gain a deeper understanding of VRNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.03 and its Current Ratio is at 13.03. In the meantime, Its Debt-to-Equity ratio is 1.72 whereas as Long-Term Debt/Eq ratio is at 1.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, ROTH MKM on January 10, 2025, initiated with a Buy rating and assigned the stock a target price of $68.
On October 03, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 05 ’24 when ZACCARDELLI DAVID sold 640,264 shares for $5.01 per share. The transaction valued at 3,205,226 led to the insider holds 14,367,552 shares of the business.
ZACCARDELLI DAVID sold 162,800 shares of VRNA for $815,400 on Dec 06 ’24. The President and CEO now owns 14,204,752 shares after completing the transaction at $5.01 per share. On Dec 04 ’24, another insider, ZACCARDELLI DAVID, who serves as the President and CEO of the company, sold 67,608 shares for $5.00 each. As a result, the insider received 338,162 and left with 15,007,816 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 4904962048 and an Enterprise Value of 39025950720. For the stock, the TTM Price-to-Sale (P/S) ratio is 863.54 while its Price-to-Book (P/B) ratio in mrq is 37.59. Its current Enterprise Value per Revenue stands at 6939.181 whereas that against EBITDA is -259.659.
Stock Price History:
The Beta on a monthly basis for VRNA is 0.43, which has changed by 2.6095471 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, VRNA has reached a high of $60.81, while it has fallen to a 52-week low of $11.39. The 50-Day Moving Average of the stock is 30.23%, while the 200-Day Moving Average is calculated to be 105.64%.
Shares Statistics:
It appears that VRNA traded 1.23M shares on average per day over the past three months and 1274210 shares per day over the past ten days. A total of 81.83M shares are outstanding, with a floating share count of 68.91M. Insiders hold about 15.79% of the company’s shares, while institutions hold 67.31% stake in the company. Shares short for VRNA as of 1736899200 were 8221321 with a Short Ratio of 6.67, compared to 1734048000 on 6625070. Therefore, it implies a Short% of Shares Outstanding of 8221321 and a Short% of Float of 10.4899995.
Earnings Estimates
The performance of Verona Pharma Plc ADR (VRNA) in the stock market is under the watchful eye of 7.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.01 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$1.87 and -$2.26 for the fiscal current year, implying an average EPS of -$2.07. EPS for the following year is -$0.37, with 7.0 analysts recommending between $0.27 and -$2.17.
Revenue Estimates
For the next quarter, 8 analysts are estimating revenue of $35.47M. There is a high estimate of $40.41M for the next quarter, whereas the lowest estimate is $29.55M.
Based on 8 analysts’ estimates, the company’s revenue will be $195.09M in the next fiscal year. The high estimate is $261.83M and the low estimate is $109.39M.
